Hypertension comorbidity
Conditions
Interventions
Intervention group:Conventional medication guidance + lifestyle guidance+medication treatment management services + pharmacist assistance for patient self-management.
Control group:Conventional medication guidance + lifestyle guidance
Sponsors
The Second A fliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Participants must meet all of the following criteria to be enrolled in this study 1. Age =18 years old, male or female; 2. Patients with essential hypertension who meet the diagnostic criteria of hypertension in the Chinese Guidelines for the Prevention and Treatment of Hypertension (Revised Edition 2024), who are not receiving treatment or are receiving antihypertensive drugs; 3. Hypertension patients with substandard blood pressure: family blood pressure > 140/90mmHg at least once in the past month, or average sitting blood pressure =140/90mmHg on the day of enrollment; 4. except for the diagnosis of essential hypertension; There are at least one chronic disease (such as coronary heart disease, heart failure, diabetes, chronic kidney disease (CKD), dyslipidemia, hyperuricemia and other chronic diseases); 5. Expected survival > 12 months; 6. The patient's condition is stable, clear consciousness, no communication and communication barriers. 7. Agree to participate in this research project and sign the informed consent.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following exclusion criteria will not be enrolled in this study 1.Severe hypertension (mean SBP=180mmHg, or mean DBP=110mmHg), acute hypertension or subacute hypertension (systolic blood pressure > 180mmHg or diastolic blood pressure > 120mmHg); 2.History or diagnostic basis of secondary hypertension, including but not limited to the following conditions: renal parenchymatous hyperemia Blood pressure, renal vascular hypertension, aortic stenosis, pheochromocytoma, Cushing's syndrome, cystic nephropathy, etc., but drug-induced hypertension was not used as exclusion criteria 3.Mental disorders, hearing impairment, intellectual impairment, aphasia, etc., resulting in inability to communicate or comply with the research agreement Discuss the patient; 4.Patients with severe liver and renal insufficiency (CKD stage 4, 5) or malignant tumors and other critical diseases that cannot withstand the process and impact of evaluation; 5.Have been diagnosed with New York Heart Association (NYHA) Class III or IV heart failure; 6. Any other reasons that the investigator believes may affect the efficacy and safety evaluation of this study are not suitable for participating in this clinical trial (including but not limited to patients who are judged by the investigator to live far away and cannot follow the schedule, and patients who are also participating in other clinical trials). Subjects who meet any of the following withdrawal criteria and are confirmed by the investigator to withdraw from the study:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in mean seated systolic blood pressure (SBP) ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in mean seated diastolic blood pressure (DBP) at,3,6 months;;Changes in the number of medication-related problems (MRPs) at 6 months versus baseline;the average number of medication-related problems (MRPs) resolved at 6 months;Change in quality of life scores (EQ-5D-5L) for patients with comorbid hypertension at 3,6 months compared to baseline.;Incidence of adverse reactions;Change from baseline in mean seated systolic blood pressure (SBP) at 3 months.;Changes in self-management behavior scores for patients with hypertension at 3 and 6 months compared to baseline;Changes in medication adherence scores from baseline at 1, 3, and 6 months later.; | — |
Countries
China
Contacts
Public ContactZhang Yin
The Second filiated Hospital of Fujian Medical University
Outcome results
None listed